RNA Interference (RNAi) Drug Delivery Market

Published Apr 01, 2026

Length 150 Pages

SKU # IMRC21133440

Description

The global RNA interference (RNAi) drug delivery market size reached USD 117.5 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 504.2 Billion by 2034, exhibiting a growth rate (CAGR) of 17.04% during 2026-2034.

Ribonucleic acid interference (RNAi) drug delivery refers to a therapeutic solution to monitor gene expression or mutations. RNAi drug delivery is usually administered through intravenous, intra-dermal and intraperitoneal injections and topical delivery methods. It involves nanoparticle, pulmonary, nucleic acid and aptamer drug delivery technologies. These technologies are also used for analyzing gene functions in eukaryotes and developing therapeutic gene silencing solutions. As a result, RNAi drug delivery is widely used for treating infectious diseases, chronic metabolic disorders, cardiovascular, neurological, urological, oncological and ophthalmological disorders.

The increasing prevalence of chronic medical and genetic disorders, such as cancer and cardiovascular diseases (CVDs) across the globe, represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, as the coronavirus disease (COVID-19) continues to spread across the globe, there has been a significant increase in the demand for RNAi drug delivery technologies. Targeted delivery methods, such as aptamer drug delivery systems, are gaining immense traction for the administration of antiviral drugs as they are induced by small interfering RNA (siRNA) that can inhibit the expression of viral antigens. Additionally, various technological advancements, such as the development of innovative synthetic delivery carriers and bio-vectors, are anticipated to drive the market growth. The nanocarriers, including siRNA or microRNAs (miRNA), are crucial for developing personalized medicines and identifying altered cellular molecules and metabolites. Other factors, including extensive research and development (R&D) activities in the fields of nanotechnology and molecular diagnostics, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

KEY MARKET SEGMENTATION:

IMARC Group provides an analysis of the key trends in each sub-segment of the global RNA interference (RNAi) drug delivery market report, along with forecasts at the global, regional and country level from 2026-2034. Our report has categorized the market based on application and technology.

Breakup by Application:

Infectious Disease
Cardiology
Oncology
Neurology
Ophthalmology
Urology
Metabolic Disorders
Others

Breakup by Technology:

Nanoparticle Drug Delivery
Pulmonary Drug Delivery
Nucleic Acid Drug Delivery
Aptamer Drug Delivery

Breakup by Region:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

COMPETITIVE LANDSCAPE:

The report provides a comprehensive analysis of the competitive landscape in the global RNA interference (RNAi) drug delivery market with detailed profiles of all major companies, including:

Alnylam Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc.
Calando Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc.
Phio Pharmaceuticals
Silence Therapeutics
Sirnaomics
Switch Therapeutics

1 Preface
2 Scope and Methodology: 2.1 Objectives of the Study; 2.2 Stakeholders; 2.3 Data Sources; 2.3.1 Primary Sources; 2.3.2 Secondary Sources; 2.4 Market Estimation; 2.4.1 Bottom-Up Approach; 2.4.2 Top-Down Approach; 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction: 4.1 Overview; 4.2 Key Industry Trends
5 Global RNA Interference (RNAi) Drug Delivery Market: 5.1 Market Overview; 5.2 Market Performance; 5.3 Impact of COVID-19; 5.4 Market Forecast
6 Market Breakup by Application: 6.1 Infectious Disease; 6.1.1 Market Trends; 6.1.2 Market Forecast; 6.2 Cardiology; 6.2.1 Market Trends; 6.2.2 Market Forecast; 6.3 Oncology; 6.3.1 Market Trends; 6.3.2 Market Forecast; 6.4 Neurology; 6.4.1 Market Trends; 6.4.2 Market Forecast; 6.5 Ophthalmology; 6.5.1 Market Trends; 6.5.2 Market Forecast; 6.6 Urology; 6.6.1 Market Trends; 6.6.2 Market Forecast; 6.7 Metabolic Disorders; 6.7.1 Market Trends; 6.7.2 Market Forecast; 6.8 Others; 6.8.1 Market Trends; 6.8.2 Market Forecast
7 Market Breakup by Technology: 7.1 Nanoparticle Drug Delivery; 7.1.1 Market Trends; 7.1.2 Market Forecast; 7.2 Pulmonary Drug Delivery; 7.2.1 Market Trends; 7.2.2 Market Forecast; 7.3 Nucleic Acid Drug Delivery; 7.3.1 Market Trends; 7.3.2 Market Forecast; 7.4 Aptamer Drug Delivery; 7.4.1 Market Trends; 7.4.2 Market Forecast
8 Market Breakup by Region: 8.1 North America; 8.1.1 United States; 8.1.1.1 Market Trends; 8.1.1.2 Market Forecast; 8.1.2 Canada; 8.1.2.1 Market Trends; 8.1.2.2 Market Forecast; 8.2 Asia Pacific; 8.2.1 China; 8.2.1.1 Market Trends; 8.2.1.2 Market Forecast; 8.2.2 Japan; 8.2.2.1 Market Trends; 8.2.2.2 Market Forecast; 8.2.3 India; 8.2.3.1 Market Trends; 8.2.3.2 Market Forecast; 8.2.4 South Korea; 8.2.4.1 Market Trends; 8.2.4.2 Market Forecast; 8.2.5 Australia; 8.2.5.1 Market Trends; 8.2.5.2 Market Forecast; 8.2.6 Indonesia; 8.2.6.1 Market Trends; 8.2.6.2 Market Forecast; 8.2.7 Others; 8.2.7.1 Market Trends; 8.2.7.2 Market Forecast; 8.3 Europe; 8.3.1 Germany; 8.3.1.1 Market Trends; 8.3.1.2 Market Forecast; 8.3.2 France; 8.3.2.1 Market Trends; 8.3.2.2 Market Forecast; 8.3.3 United Kingdom; 8.3.3.1 Market Trends; 8.3.3.2 Market Forecast; 8.3.4 Italy; 8.3.4.1 Market Trends; 8.3.4.2 Market Forecast; 8.3.5 Spain; 8.3.5.1 Market Trends; 8.3.5.2 Market Forecast; 8.3.6 Russia; 8.3.6.1 Market Trends; 8.3.6.2 Market Forecast; 8.3.7 Others; 8.3.7.1 Market Trends; 8.3.7.2 Market Forecast; 8.4 Latin America; 8.4.1 Brazil; 8.4.1.1 Market Trends; 8.4.1.2 Market Forecast; 8.4.2 Mexico; 8.4.2.1 Market Trends; 8.4.2.2 Market Forecast; 8.4.3 Others; 8.4.3.1 Market Trends; 8.4.3.2 Market Forecast; 8.5 Middle East and Africa; 8.5.1 Market Trends; 8.5.2 Market Breakup by Country; 8.5.3 Market Forecast
9 SWOT Analysis: 9.1 Overview; 9.2 Strengths; 9.3 Weaknesses; 9.4 Opportunities; 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis: 11.1 Overview; 11.2 Bargaining Power of Buyers; 11.3 Bargaining Power of Suppliers; 11.4 Degree of Competition; 11.5 Threat of New Entrants; 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape: 13.1 Market Structure; 13.2 Key Players; 13.3 Profiles of Key Players; 13.3.1 Alnylam Pharmaceuticals, Inc.; 13.3.1.1 Company Overview; 13.3.1.2 Product Portfolio; 13.3.1.3 Financials; 13.3.1.4 SWOT Analysis; 13.3.2 Arrowhead Pharmaceuticals, Inc.; 13.3.2.1 Company Overview; 13.3.2.2 Product Portfolio; 13.3.2.3 Financials; 13.3.3 Calando Pharmaceuticals Inc; 13.3.3.1 Company Overview; 13.3.3.2 Product Portfolio; 13.3.3.3 Financials; 13.3.3.4 SWOT Analysis; 13.3.4 Ionis Pharmaceuticals, Inc.; 13.3.4.1 Company Overview; 13.3.4.2 Product Portfolio; 13.3.4.3 Financials; 13.3.4.4 SWOT Analysis; 13.3.5 Phio Pharmaceuticals; 13.3.5.1 Company Overview; 13.3.5.2 Product Portfolio; 13.3.5.3 Financials; 13.3.5.4 SWOT Analysis; 13.3.6 Silence Therapeutics; 13.3.6.1 Company Overview; 13.3.6.2 Product Portfolio; 13.3.6.3 Financials; 13.3.7 Sirnaomics; 13.3.7.1 Company Overview; 13.3.7.2 Product Portfolio; 13.3.8 Switch Therapeutics; 13.3.8.1 Company Overview; 13.3.8.2 Product Portfolio; 13.3.8.3 Financials; 13.3.8.4 SWOT Analysis

Pricing

Currency Rates

Single User Email from Publisher $3,999
Five User License Fulfilled by Publisher $4,999
Global Site License Email from Publisher $5,999

How Do Licenses Work?

Request A Sample

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.

Chat Now